Breakthrough findings open doors to multi-billion-dollar infection-control markets SALT LAKE CITY, Utah, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced the publication of a peer-reviewed study demonstrating that silicon nitride exhibits potent antiviral activity against multiple infectious virus strains, including SARS-CoV-2 and MERS-CoV. ...

The Company expects similar results can be obtained with a wide variety of other thermoplastics, including polyetheretherketone (PEEK). This particulate embedding approach represents an additional way to impart silicon nitride's beneficial biologic properties to conventional inert biomaterials. "The significance of this study is twofold—it affirms that silicon nitride can be effectively integrated with novel thermoplastic-based biomaterials, and it supports our broader vision of combination materials tailor ...

Core Insights - SINTX Technologies has announced a renewed corporate vision and strategic plan aimed at accelerating the commercialization of its proprietary silicon nitride technologies following a successful recapitalization and leadership restructuring [1][5]. Company Overview - SINTX Technologies is the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, with a history of innovation dating back to 2008 when it introduced the first FDA-cleared implant material made from medical-grade silicon nitride [1][2][3]. - The company holds 18 issued U.S. patents and has 84 pending applications, positioning itself as an industry leader in silicon nitride technology with applications across various markets, including a $62 billion global orthopedic implant sector [3]. Strategic Initiatives - The company is focusing on developing next-generation hybrid biomaterials that combine the biological performance of silicon nitride with the flexibility of polymers like PEEK and PEKK, targeting applications in spine, oral/maxillofacial, cranio-maxillofacial, and oncologic reconstruction [4][5]. - SINTX is pursuing strategic partnerships and licensing opportunities to expand its technology reach, with initiatives including joint ventures in orthopedics, wound care, and agribiotech, as well as monetizing its extensive patent portfolio [5][8]. Commitment to Stakeholders - The company emphasizes its commitment to transparency, disciplined execution, and long-term value creation for all stakeholders, expressing gratitude for the support from shareholders and partners [6].

Core Insights - SINTX Technologies has announced the issuance of International Patent No. 7635292, covering novel agricultural uses of silicon nitride (Si₃N₄) for plant protection and antimicrobial treatment, complementing U.S. Patent No. 11,591,217 [1][2] - The company is launching a wholly-owned subsidiary, SINTX Agribiotech, Inc., to focus on developing and commercializing agricultural and environmental technologies [2][4] - The global antimicrobial fertilizer and crop protection market is projected to reach $10.36 billion by 2030, presenting a significant market opportunity for SINTX's Si₃N₄ technology [3] Company Strategy - The new agribiotech subsidiary will operate independently from SINTX's medical device business, allowing for focused resource allocation and potential partnerships with agricultural companies [4] - The company aims to deploy Si₃N₄ in various agricultural settings, starting with wine production, leveraging its antifungal properties against grapevine diseases [5][6] Product Advantages - SINTX's Si₃N₄ formulation offers broad-spectrum antimicrobial action without damaging plant tissue, positioning it as a sustainable alternative to traditional copper-based fungicides [6] - Internal research indicates that Si₃N₄ can reduce the growth and sporulation of the grapevine pathogen Plasmopara viticola by 80-90%, with complete protection observed in select trials [5][6]

Core Insights - Sintx Technologies, Inc. announced the retirement of Dr. Sonny Bal as Chairman of the Board, with Eric Olson, the current CEO, appointed as the new Chairman effective immediately [1][2] Leadership Transition - Dr. Bal has been Chairman since 2015 and has significantly contributed to Sintx's transformation and growth in advanced materials [2] - Eric Olson expressed gratitude for Dr. Bal's leadership and emphasized the company's focus on high-value medical applications and strategic partnerships moving forward [3] - Since becoming CEO in August 2024, Olson has redirected the company towards high-growth opportunities in biomedical and medical device sectors [3] Company Overview - Sintx Technologies specializes in advanced ceramics for medical applications and is a leader in the research and manufacturing of silicon nitride, with products implanted in humans since 2008 [4] - The company has pursued strategic acquisitions and alliances to expand into new markets [4]

Salt Lake City, Utah, Feb. 26, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc., (“SINTX” or the “Company”) (Nasdaq: SINT), a leader in advanced ceramics for medical applications, today announced that it has, pursuant to a securities purchase agreement with institutional and accredited investors dated February 20, 2025, issued and sold 1,449,287 shares of common stock (or pre-funded warrants in lieu therof) at a purchase price of $3.45 per share (or pre-funded warrant in lieu thereof) in a private placemen ...